Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 13/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 10/20 | 0.46 |
| ▸ | ITK | Q08881 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013381 | 1.00 | AURKA (0.46) | AURKAAURKBITKMAPTBRD4 | |
| SCHEMBL1461080 | 0.85 | AURKA (0.52) | AURKAAURKBITKMAPTBRD4 | |
| SCHEMBL1461078 | 0.85 | AURKA (0.52) | AURKAAURKBITKMAPTBRD4 | |
| Hydrochloric Acid SCHEMBL4152154 | 0.84 | AURKA (0.51) | AURKAAURKBITKMAPTBRD4 | |
| SCHEMBL1460658 | 0.82 | AURKA (0.67) | AURKAAURKBITKBRD4 | |
| SCHEMBL1460655 | 0.82 | AURKA (0.67) | AURKAAURKBITKBRD4 | |
| SCHEMBL4013378 | 0.81 | AURKA (0.48) | AURKAAURKBITKMAPTBRD4 | |
| SCHEMBL6554384 | 0.81 | HAO1 (0.56) | AURKAAURKBITKBRD4 | |
| SCHEMBL4005787 | 0.80 | ITK (0.46) | AURKAAURKBITKBRD4MEN1 | |
| SCHEMBL4013164 | 0.80 | ITK (0.46) | AURKAAURKBITKMAPTBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473701-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | AURKA 65/4885AURKB 67/4885ITK 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.